CAR-T cell therapy for lupus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests a treatment called CD19/BCMA CAR-T for people with lupus (SLE) that has not improved with standard treatments. The therapy uses your own immune cells, modified to target and calm overactive immune cells, aiming to reduce disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with lupus (SLE) based on standard criteria.
- Your lupus has not responded to at least two standard treatments taken for 3 months or more.
- Your lupus is currently active, with a score of 6 or higher on a standard lupus activity scale, or you have severe or moderate organ involvement.
- Your major organs (bone marrow, liver, kidneys, heart) are working well enough to safely receive the treatment.
- You are not pregnant, and you agree to use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell treatment made from donor umbilical cord blood for people with lupus that hasn't improved with at least two standard treatments. The goal is to see if it can help control disease activity.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are modified to target two proteins (CD19 and BCMA) on lupus cells. It is for people with lupus nephritis (kidney inflammation) that has not improved after trying multiple standard treatments.
This study tests a new type of immune cell therapy (CAR-T cells) designed to target and reduce the immune cells driving lupus in patients whose disease hasn't responded to standard treatments. Researchers will first identify which specific immune cells are causing your lupus, then engineer your own immune cells to fight them.
This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.
This trial tests whether a type of immune cell therapy called CAR-T can help people with active lupus that hasn't responded well to standard treatments. It aims to reduce disease activity and improve symptoms.
Hear when a new SLE - Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.